TrialCancer research communications2025

Phase II Study Evaluating the Efficacy of Niraparib and Dostarlimab (TSR-042) in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma.

Olga Zamulko et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.